Giant cell tumour of the sacrum: Function-preserving surgery with extended curettage and ilio-lumbar fusion

Giant cell tumours of the sacrum pose a unique therapeutic challenge due to the inaccessibility of the tumour, significant intra-operative blood loss from extensive vascularity, high rate of local recurrence with conservative surgery, and loss of neurological function and mechanical instability with en-bloc excision. We present a case where successful outcome was achieved by tailoring treatment in consideration of the above issues. A 28 year old male diagnosed on biopsy to have giant cell tumour of the sacrum presented to us with low-back pain, left-sided S1 radiculopathy, ankle weakness and urinary incontinence. MRI showed a tumour involving the S1 and S2 vertebral segments, breaching the posterior cortex and compressing the neural elements. An angiographic tumour embolization was performed followed by surgery through a posterior approach whereby an extended curettage was done, carefully freeing the sacral nerve roots and abrading the bone using high-speed burr. An ilio-sacro-lumbar fusion was done employing iliolumbar instrumentation and bone grafting. Post-operatively, within a week the patient was ambulated with a lumbar corset. At 9 months follow-up, the patient was completely pain free, had no ankle weakness, and had normal continence. This treatment approach resulted in preservation of neurologic function and maintenance of spinal stability, thus the patient returned to full function

Cytomorphological Diagnosis of Giant Cell Tumour of Distal End Radius in Elderly Patient

Giant cell tumours (GCTs) of bone have been described as the most challenging benign bone tumors. It is very unusual for GCT to occur in patients younger than 20 yrs or older than 55 years. GCT is seen with a slightly increased frequency in females. The typical giant cell tumor (GCT) is a solitary neoplasm that occurs in the epiphysis or metaphysis of long bones. The most common sites include the distal femur, proximal tibia and distal radius. The sacrum, distal tibia, proximal humerus, proximal femur, pelvis and proximal fibula are not infrequent sites. Here we report cytologically diagnosed case of GCT distal end radius in 75 yrs male patient. We discuss its clinicopathologic features, differential diagnosis and its optimal treatment

Giant-cell tumour of proximal radius in a 50-year-old female with wrist drop: a rare case report

Abstract Giant-cell tumour is a locally aggressive tumour of long bones of epiphyseal region commonly occurring in adults aged 20–40 years. Most common location is distal femur, proximal tibia, and distal radius. Different treatment options being used are curettage with bone graft or bone cement, resection with arthrodesis, reconstruction, radiation, and chemotherapy. We are reporting a case of giant-cell tumour of right proximal radius in a 50-year-old female with posterior interosseous nerve palsy. It is very rare, and only four cases have been reported in the literature. It was treated by wide margin resection with fibular grafting, titanium elastic nail system along with cancellous bone graft reconstruction

Malignização primária no tumor de células gigantes: um estudo de caso

CONTEXT: Primary malignancy in giant cell tumor (PMGCT) is rare. It is defined as a high-grade sarcoma originating in a giant cell tumor (GCT) and seems to behave less aggressively than its secondary counterpart does. CASE REPORT: This report presents the case of a 39-year-old female with pain in her left shoulder for one month. Radiography showed a pathological fracture of the proximal humerus associated with an osteolytic lesion. Histopathological analysis showed typical areas of GCT juxtaposed with a sarcomatous component. CONCLUSIONS: PMGCT seems to behave less aggressively than secondary malignancy in GCT, and it may simulate its more common benign counterpart clinically and radiographically. However, it requires a more aggressive type of treatment.CONTEXTO: Malignização primária no tumor de células gigantes (MPTCG) é rara. Ela é definida como um sarcoma de alto grau originário de um tumor de células gigantes que parece ser menos agressivo que o tipo secundário. RELATO DE CASO: Relatamos um caso de uma paciente de 39 anos de idade, com dor no ombro esquerdo há um mês. A radiografia mostrou uma fratura patológica do úmero proximal associada a uma lesão osteolítica. O exame histopatológico revelou típicas áreas de tumor de células gigantes justapostas por um componente sarcomatoso. CONCLUSÃO: MPTCG parece se comportar menos agressivamente que a neoplasia secundária do tumor de células gigantes (TCG), e pode simular o TCG, que é mais comum, tanto clínica como radiograficamente. Entretanto, exige tratamento mais agressivo

Giant cell tumour with intra-articular extension: a case report

Giant cell tumour is usually a benign but locally aggressive tumour. Intra-articular extension of giant cell tumour is rare. Treatment options are limited in such cases. I present here a 33 year old male with a history of swelling around his right knee for 6 months. Patient was diagnosed clinically, radiologically and histologically as giant cell tumour. Patient was treated by surgical excision of the tumour and reconstruction with custom mega prosthesis

Case of giant cell tumour of proximal tibia treated with intra-lesion curettage with adjuvant therapy and reconstruction with the sandwich technique fixation

Giant cell tumour (GCT) of bone is a benign but locally aggressive tumour with the potential of malignant transformation that mostly involves the meta-epiphyseal region of long bones. A 34-year-old female was presented to our institute with progressive pain and swelling in her right knee and was radiologically and histologically found to have a GCT of proximal tibia. She was treated with extended curettage with power burr, intra-lesion phenol application and internal fixation using the sandwich technique. No recurrence was found and the procedure led to a good functional outcome. A GCT of proximal tibia treated with joint preserving surgery with extended curettage and the sandwich technique fixation gives optimal results leading to a good functional outcome

Segmental excision versus intralesional curettage with adjuvant therapy for giant cell tumour of bone

Abstract PURPOSE: To review the functional outcome and local recurrence rate of 29 patients who underwent segmental excision or intralesionalcurettage with adjuvant therapy for giant cell tumour (GCT) of bone. METHODS: Records of 17 men and 12 women (mean age, 30.17 years) who underwent segmental excision (n=18) or intralesional curettage followed by adjuvant therapy (n=11) for GCT of the femur (n=13), tibia (n=8), radius (n=6), or ulna (n=2) were reviewed. Nine of the patients had recurrent GCT of bone and had undergone segmental excision (n=6) or intralesional curettage (n=3) elsewhere. Functional outcome was evaluated using the Musculoskeletal Tumour Society (MSTS) scoring system. RESULTS: The mean follow-up period was 6.4 (range, 3-13.5) years. 14 patients were followed up for 3 to 5 years, 12 for 5 to 10 years, and 3 for \u3e10 years. Of 20 patients with primary GCT of bone, 12 underwent segmental excision and had no recurrence, and 8 underwent intralesional curettage, 2 of whom developed local recurrence. Of the remaining 9 patients with recurrent GCT of bone, there was one re-recurrence in each surgical option. Local recurrence was not associated with Campanacci grading or type of surgery. One of 18 patients with segmental excision and 3 of 11 patients with intralesional curettage had local recurrence (5.6% vs. 27.3%, p=0.139). The MSTS score was excellent in 7, good in 6, moderate in 2, fair in 2, and poor in one patient after segmental excision, whereas the score was excellent in 9 and good in 2 patients after intralesional curettage (p=0.206). The proportion of yielding an excellent outcome was higher after intralesionalcurettage (38.9% vs. 81.8%, p=0.0289). Nonetheless, the mean MSTS score of the 2 groups was comparable (74.17% vs. 86.36%, p=0.054). CONCLUSION: Local recurrence of GCT was not associated with the surgical option. Nonetheless, intralesional curettage resulted in better functional outcome

Avaliação radiográfica e funcional de 214 lesões ósseas benignas agressivas tratadas com curetagem, cauterização e cimentação: 24 anos de seguimento

PURPOSE: Treatment with curettage, cauterization, and methylmethacrylate of aggressive benign bone lesions is a method now widely accepted in most orthopedic oncology centers. However, one of the controversies regarding this technique is the possible complications that may arise from the use of methylmethacrylate, which has caused some authors to remove it 2 years after the surgery and replace it with bone graft. The objective of this paper is to present a functional and radiographic evaluation of 214 patients presenting with aggressive benign bone lesions treated with curettage, cauterization, and methylmethacrylate from 1974 to 1998, with some of them having 24 years of follow-up. These patients were clinically and radiographically evaluated for the incidence of late osteoarthrosis, range of motion, and pain in the involved joint. METHOD: This study comprised 214 patients, with an average follow-up duration of 10.6 years (range: 2 to 24 years. All cases involved aggressive benign lesions. The patients were evaluated according to the Musculoskeletal Tumor Society Score (MSTS) functional evaluation system, and the complications are described. RESULTS: The MSTS functional evaluation was excellent in 166 cases (78%), good in 26 (12%), fair in 11 (5%), and poor in 11 (5%). The following complications were observed: late osteoarthrosis, 25 cases (12%); infection, 12 (6%); pathologic fracture, 11 (5%); and local recurrence, 19 (9%). CONCLUSION: Based on clinical assessment, no significant deleterious effects directly related to the use of methylmethacrylate were observed. The functional evaluation performed in 1998 (up to 24 years of follow-up) did not show significant change when compared to the evaluation performed in 1985.OBJETIVO: O tratamento com curetagem cauterização e metilmetacrilato de lesões ósseas benignas agressivas é o método agora amplamente aceito em quase todos os Centros Ortopédicos Oncológicos, entretanto uma das controvérsias com relação a esta técnica são as possíveis complicações que podem sugerir com o uso do metilmetacrilato fazendo com que alguns autores o removam dos anos depois da cirurgia e os substituam com o enxerto ósseo. O objetivo deste trabalho é apresentar a avaliação radiográfica e funcional de 214 pacientes apresentando lesões ósseas benignas agressivas tratadas com curetagem, cauterização e metilmetacrilato de 1974 a 1998, sendo que alguns deles tem 12 anos de seguimento. Esses pacientes foram avaliados clínica e radiograficamente para a ocorrência de osteoartrose tardia, amplitude de movimento e dor na articulação envolvida. MÉTODO: Este estudo é constituído de 214 pacientes, com seguimento médio de 10,6 anos (2 a 24 anos). Todos os casos correspondem as lesões benignas agressivas. Os pacientes foram avaliados de acordo com Muscolskeletal Tumor Society Score sendo descritas as complicações. RESULTADOS: A avaliação funcional da (MSTS) foi excelente em 166 casos (78%), bom em 26 (12%), regular em 11(5%) e mal 11 (5%). Foram observadas as seguintes complicações: osteoartrose tardia 25 casos (12%), infecção 12(6%), fratura patológica 11(5%) e rescindiva local 19(9%). CONCLUSÃO: Baseado na abordagem clínica não foi observado efeitos deletérios diretamente relacionados ao uso do metilmetacrilato. A avaliação funcional realizada em 1998 (até 24 anos de seguimento) não apresentou alterações significantes quando comparadas a avaliação realizada em 1985

Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study

The role of radiotherapy for local control of marginally resected, unresectable, and recurrent giant cell tumors of bone (GCToB) has not been well defined. The number of patients affected by this rare disease is low. We present a series of 58 patients with biopsy proven GCToB who were treated with radiation therapy. A retrospective review of the role of radiotherapy in the treatment of GCToB was conducted in participating institutions of the Rare Cancer Network. Eligibility criteria consisted of the use of radiotherapy for marginally resected, unresectable, and recurrent GCToB. Fifty-eight patients with biopsy proven GCToB were analyzed from 9 participating North American and European institutions. Forty-five patients had a primary tumor and 13 patients had a recurrent tumor. Median radiation dose was 50 Gy in a median of 25 fractions. Indication for radiation therapy was marginal resection in 33 patients, unresectable tumor in 13 patients, recurrence in 9 patients and palliation in 2 patients. Median tumor size was 7.0 cm. A significant proportion of the tumors involved critical structures. Median follow-up was 8.0 years. Five year local control was 85% . Of the 7 local failures, 3 were treated successfully with salvage surgery. All patients who received palliation achieved symptom relief. Five year overall survival was 94%. None of the patients experienced grade 3 or higher acute toxicity. This study reports a large published experience in the treatment of GCToB with radiotherapy. Radiotherapy can provide excellent local control for incompletely resected, unresectable or recurrent GCToB with acceptable morbidity